DTMT Network
Dr Reddy's Laboratories has launched Bortezomib injection 3.5 mg/vial for treatment of multiple myeloma and mantle cell lymphoma. The drug has been launched after it was approved by the US Food and Drug Administration.

“We’re pleased to bring this product to market for the customers and patients who will benefit from this cost efficient alternative in the market place,” said Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy’s Laboratories.

“This is a great addition to our injectable offering in the U.S. market as we continue to augment our portfolio of products in the Hospital segment,” added Kikuchi.

Bortezomib for Injection 3.5 mg/vial is for intravenous use only and is indicated for the treatment of adult patients with multiple myeloma and for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.